Autobio Diagnostics Co

Autobio Diagnostics Co Receivables

The Accounts Receivable of Autobio Diagnostics Co (603658.SS) as of Oct 21, 2026 is 1.14 B CNY. In the previous year, Accounts Receivable was 1.15 B CNY — a change of -1.24% (lower).

Receivables

1.14 BCNY

YoY

-1.24%

Last updated:

Accounts Receivable of Autobio Diagnostics Co is 2024 1.14 B CNY. Accounts Receivable of Autobio Diagnostics Co was 2023 1.15 B CNY. It decreases by -1.24% lower compared to the previous year.

The Autobio Diagnostics Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
224.40 M CNY
Jan 1, 2018
345.50 M CNY
Jan 1, 2019
634.50 M CNY
Jan 1, 2020
956.30 M CNY
Jan 1, 2021
989.06 M CNY
Jan 1, 2022
1.05 B CNY
Jan 1, 2023
1.15 B CNY
Jan 1, 2024
1.14 B CNY
The Autobio Diagnostics Co Receivables history
YEARReceivablesYoY
1.14 BCNY-1.24%
1.15 BCNY+9.58%
1.05 BCNY+6.41%
989.06 MCNY+3.43%
956.30 MCNY+50.72%
634.50 MCNY+83.65%
345.50 MCNY+53.97%
224.40 MCNY+38.86%
161.60 MCNY+53.32%
105.40 MCNY+24.88%
84.40 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Autobio Diagnostics Co Stock analysis

What does Autobio Diagnostics Co do? Autobio Diagnostics Co., Ltd. generates revenue through the sale of in vitro diagnostic reagents and instruments, including gnostic products, microbiology detection products, and related devices. The company's immunodiagnostic products consist of microplate chemiluminescence diagnostic reagents, Enzyme-Linked immunosorbent assay diagnostic reagents, magnetic particle chemiluminescence detection reagents, and colloidal diagnostic reagents. Microbiology detection products feature training detection reagents, susceptibility detection reagents, and rapid detection reagents. Device products include microplate readers, chemiluminescence immunoassay analyzers, and united testing analyzers, all distributed within domestic markets. The firm targets domestic healthcare providers and laboratories as primary buyers of its diagnostic reagents and instruments. Its core products serve clinical diagnostics needs for infectious disease testing, microbial identification, and immune response analysis. The company's product portfolio emphasizes domestic market distribution, with no mention of international sales channels or export activities. Autobio Diagnostics' revenue streams are derived from the manufacturing and distribution of diagnostic reagents, instruments, and related devices. The company focuses on domestic market penetration through its product range, which includes specialized reagents for microbiology and immunodiagnosis. No additional revenue sources such as service contracts or software licensing are indicated in the business description. Autobio Diagnostics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Autobio Diagnostics Co stock

Accounts Receivable of Autobio Diagnostics Co is 1.14 B CNY in 2024.

Accounts Receivable of Autobio Diagnostics Co changed from 1.15 B CNY to 1.14 B CNY, representing a -1.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Autobio Diagnostics Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Autobio Diagnostics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Autobio Diagnostics Co

All Key Metrics — Autobio Diagnostics Co